Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo

We aimed to identify potent biliverdin reductase (BVRA) inhibitors as a novel concept for the treatment of severe unconjugated hyperbilirubinemia. 1280 FDA-approved compounds were screened in vitro for their ability to inhibit human and rat BVRA activity and 26 compounds were identified as BVRA in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: van Dijk, Remco, Aronson, Sem J., de Waart, Dirk R., van de Graaf, Stan F., Duijst, Suzanne, Seppen, Jurgen, Elferink, Ronald Oude, Beuers, Ulrich, Bosma, Piter J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5431759/
https://ncbi.nlm.nih.gov/pubmed/28490767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-01602-w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak